Sachi develops novel COVID-19 treatment

April 25th, 2021

Sachi Bioworks has developed a novel host microRNA targeting treatment to reduce SARS-CoV2 infection. Check out paper in BioRxiv! This therapy was developed in collaboration with researchers in NASA, Cornell University, University of North Carolina, Rice University, MIT, Broad Institute, University of Texas MD Anderson Cancer Center, Johns Hopkins University, University of Chicago, and many other leading institutions worldwide.

The Great Deceiver: miR-2392's Hidden Role in Driving SARS-CoV-2 Infection


MicroRNAs (miRNAs) are small non-coding RNAs involved in post-transcriptional gene regulation that have a major impact on many diseases and provides an exciting avenue towards antiviral therapeutics. From patient transcriptomic data, we have discovered a circulating miRNA, miR-2392, that is directly involved with SARS-CoV-2 machinery during host infection. Specifically, we found that miR-2392 was key in driving downstream suppression of mitochondrial gene expression, increasing inflammation, glycolysis, and hypoxia as well as promoting many symptoms associated with COVID-19 infection. We demonstrate miR-2392 is present in the blood and urine of COVID-19 patients tested, but not detected in COVID-19 negative patients. These findings indicate the potential for developing a novel, minimally invasive, COVID-19 detection method. Lastly, using both in vitro human and in vivo hamster models, we have developed a novel miRNA-based antiviral therapeutic targeting miR-2392 that significantly reduces SARS-CoV-2 viability and may potentially inhibit a COVID-19 disease state in the host.

Read article

45 views0 comments

Recent Posts

See All